GlaxoSmithKline has increased its share of Theravance, with which it is developing Relovair fluticasone/vilanterol COPD product, to approximately 19%. In addition, GSK is crediting a UK "patent box" proposal to encourage R&D investments with in announcing its final decision to invest in its facility in Ware, Hertfordshire for the manufacture of the new inhalation device for the product. Read the company’s press release on Theravance and the press release on the "patent box" investments.
GSK increases investment in Relovair development
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
